Author

Jessica Cai

Institution: Regeneron (United States)

Observed institution: Regeneron (United States)

OpenAlex ID: A5111224933

Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

2023 · Jose. C. Villasboas, Tae Min Kim, et al. · Blood · 14

Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 Study

2023 · Jennifer L. Crombie, Matthew Matasar, et al. · Blood · 8

Circulating Tumor DNA Analysis Associates with Progression-Free Survival (PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study

2023 · Jon E. Arnason, Jurriaan Brouwer-Visser, et al. · Blood · 3

Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

2023 · Benoit Tessoulin, Seok-Goo Cho, et al. · Blood · 2

Works count: 4

Citation count: 27

H-index: 3

I10-index: 1